Microaggressions at work; more than just hurt feelings
The study in brief
In what they believe to be the first study of its kind, US researchers investigated microaggressions experienced by people with MS in the workplace. Microaggressions are subtle and everyday discriminatory actions which can be difficult to identify as prejudice and can leave people unsure of what to do or how to react.
29 people with MS took part in focus groups, answering questions designed to draw out episodes of microaggression, how this affected working life and the strategies used to cope with difficulties. Conversations were analysed by researchers in collaboration with people with MS.
All the participants had encountered some sort of microaggression at work, which could be categorised as microassaults, microinsults and microinvalidations; in practice there was considerable overlap between these subtypes. Participants felt that a key factor was other people’s lack of knowledge or misperceptions about MS, but they often felt uncomfortable about disclosing MS or requesting reasonable adjustments for fear of being judged. Involvement in support groups was seen as a good way to find out how other people cope, access resources and share strategies for talking to colleagues.
The findings of the study confirm the negative impact of microaggressions on self-confidence at work, on job satisfaction and job security. The researchers call for greater awareness of microaggressions and make a number of recommendations including organisational change to provide a more positive workplace and helping people with MS improve their self-confidence and communication skills.
The study in more detail
Background
A microaggression is a subtle behaviour – verbal or non-verbal, intentional or unintentional – directed at a member of a minority group that has a derogatory, harmful effect. A slow accumulation of microaggressions can lead to low self-esteem, feelings of alienation and eventually even mental health issues. The concept was initially developed to understand subtle forms of racism but more recently has been applied to discrimination relating to sexual orientation, mental illness and physical disability.
There is growing evidence that microaggressions are common in the workplace but little is known about the experience of people with disabilities. In what they believe to be the first study of its kind, US researchers investigated microaggressions experienced by people with MS at work.
How this study was carried out
29 people from the across the States who had worked in the past three years while living with MS took part in a series of focus groups which were held either face-to-face or by video conference. Researchers and people with MS collaborated in developing a set of questions designed to draw out experiences of microaggressions in the workplace, their impact on thoughts and behaviours relating to job satisfaction and security and strategies used by people with MS to help them cope with microaggressions.
All focus groups were recorded and analysed to identify themes which emerged from the conversations.
What was found?
Participants were encouraged to categorise microaggressions into three subtypes, although in practice there was considerable overlap between them:
- Microassaults: most likely to be viewed as direct discrimination, these are often conscious statements or actions intended to hurt a person (eg a derogatory comment such as “Well c’mon, spit it out!” while trying to explain something to a colleague)
- Microinsults: often unconscious and characterised as remarks or actions that intentionally or unintentionally convey rudeness or insensitivity (eg complimenting you in a way that felt offensive – “You look so well for someone with MS”)
- Microinvalidations: typically unconscious and include comments and behaviours that discount, exclude, negate or contradict the thoughts, feelings or lived experience of a person (eg after explaining the impact of MS fatigue – “Oh I know, I get really tired too”)
All of the participants reported experiencing microaggressions in the workplace, which they primarily attributed to others’ lack of knowledge or misperceptions about MS. The vast majority saw these experiences as discriminatory and negative, increasing their level of stress, damaging working relationships and undermining their confidence in their work performance and ability to contribute. Participants also described struggling to make a decision about disclosing MS due to concerns about possible negative consequences and feeling that it was a challenge to educate co-workers and supervisors about MS symptoms and discuss reasonable adjustments that they needed.
Relatively few participants described positive experiences following disclosure of their MS, although the researchers suggest this might have been due in part to the nature of the focus group questions.
Involvement in support groups was the most popular coping strategy and was seen as a good way to find out about resources available to support people working with MS and share strategies for explaining MS to colleagues and supervisors. Other coping strategies included meditation, exercise, positive self-talk and support from family members.
What does it mean?
The results from this study highlight the negative impact that workplace microaggressions can have on job satisfaction and security. The ambiguous nature of microaggressions means that people often doubt their reactions and are less likely to report incidents to managers, limiting the opportunities to change attitudes.
The researchers make a number of recommendations for tackling microaggressions, including creating a more positive and inclusive workplace climate through organisational change and working directly with people with MS to help them improve their self-confidence and skills to communicate the impact of MS and negotiate reasonable adjustments.
Lee EJ, Ditchman N, Thomas J, Tsen J.
Microaggressions experienced by people with multiple sclerosis in the workplace: An exploratory study using Sue's taxonomy.
Rehabilitation Psychology 2019 May;64(2):179-193.
Summary
More about working with MS
Working with MS can be challenging, but there is help and advice to help you manage life in the workplace.
You can read more about working with MS in our Working life information online.
This covers how MS could affect you at work, suggestions for explaining MS to your employer, your rights at work and things you can do to look after yourself.
The MS Society offers a toolkit of decision tools and information sheets for employees with MS and their employers.
Browse more from the latest research
Causes of MS
Harroud A, Morris JA, Forgetta V, Mitchell R, Smith GD, Sawcer SJ, Richards JB.
Effect of age at puberty on risk of multiple sclerosis: A mendelian randomization study.
Neurology. 2019 Mar 20. pii: 10.1212/WNL.0000000000007325. doi: 10.1212/WNL.0000000000007325. [Epub ahead of print]
Summary(link is external)
Cortese M, Chitnis T, Ascherio A, Munger KL.
Total intake of different minerals and the risk of multiple sclerosis.
Neurology. 2019 Apr 3. pii: 10.1212/WNL.0000000000006800. doi: 10.1212/WNL.0000000000006800. [Epub ahead of print]
Summary(link is external)
CCSVI
Hynes SM, Ghahari S, Forwell SJ.
"Waiting for Science to Catch up with Practice": an examination of 10-year YouTube trends in discussions of chronic cerebral spinal venous insufficiency treatment for multiple sclerosis.
Inform Health Soc Care. 2019 Mar 26:1-11. doi: 10.1080/17538157.2019.1582052. [Epub ahead of print]
Summary(link is external)
Childhood MS
Brenton JN, Woolbright E, Briscoe-Abath C, Qureshi A, Conaway M, Goldman MD.
Body mass index trajectories in pediatric multiple sclerosis.
Dev Med Child Neurol. 2019 Apr 5. doi: 10.1111/dmcn.14233. [Epub ahead of print]
Summary(link is external)
Bartels F, Nobis K, Cooper G, Wendel E, Cleaveland R, Bajer-Kornek B, Blaschek A, Schimmel M, Blankenburg M, Baumann M, Karenfort M, Finke C, Rostásy K.
Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.
Mult Scler. 2019 Apr 4:1352458519829698. doi: 10.1177/1352458519829698. [Epub ahead of print]
Summary(link is external)
Duignan S, Brownlee W, Wassmer E, Hemingway C, Lim M, Ciccarelli O, Hacohen Y.
Paediatric multiple sclerosis: a new era in diagnosis and treatment.
Dev Med Child Neurol. 2019 Apr 1. doi: 10.1111/dmcn.14212. [Epub ahead of print] Review.
Summary(link is external)
Co-existing conditions
Marrie RA.
Comorbidity in multiple sclerosis: Past, present and future.
Clin Invest Med. 2019 Mar 23;42(1):E5-E12. doi: 10.25011/cim.v42i1.32383.
Summary(link is external)
Diagnosis
Almeida MN, Silvernale C, Kuo B, Staller K.
Bowel symptoms predate the diagnosis among many patients with multiple sclerosis: A 14-year cohort study.
Neurogastroenterol Motil. 2019 Apr 8:e13592. doi: 10.1111/nmo.13592. [Epub ahead of print]
Summary(link is external)
Schwenkenbecher P, Wurster U, Konen FF, Gingele S, Sühs KW, Wattjes MP, Stangel M, Skripuletz T.
Impact of the McDonald Criteria 2017 on early diagnosis of relapsing-remitting multiple sclerosis.
Front Neurol. 2019 Mar 15;10:188. doi: 10.3389/fneur.2019.00188. eCollection 2019. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Disease modifying drugs
Vukusic S, Coyle PK, Jurgensen S, Truffinet P, Benamor M, Afsar S, Purvis A, Poole EM, Chambers C.
Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055. [Epub ahead of print]
Summary(link is external)
Alamo A, Condorelli RA, La Vignera S, Calogero AE.
Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419843690. doi: 10.1177/2058738419843690.
Summary(link is external)
Read the full text of this paper (link is external)
Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H.
Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.
Ther Adv Neurol Disord. 2019 Apr 1;12:1756286419836571. doi: 10.1177/1756286419836571. eCollection 2019. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV.
Best practices for long-lerm monitoring and follow-up of alemtuzumab-treated MS patients in real-world clinical settings.
Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR)..
Real life use of oral disease modifying treatments in Austria.
Acta Neurol Scand. 2019 Apr 8. doi: 10.1111/ane.13097. [Epub ahead of print]
Summary(link is external)
Mazdeh M, Kargar Monhaser S, Taheri M, Ghafouri-Fard S.
A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients.
Clin Transl Med. 2019 Apr 8;8(1):11. doi: 10.1186/s40169-019-0228-7.
Summary(link is external)
Read the full text of this paper (link is external)
Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S.
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.
Ther Adv Neurol Disord. 2019 Mar 29;12:1756286419837809. doi: 10.1177/1756286419837809. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Blankenbach K, Schwab N, Hofner B, Adams O, Keller-Stanislawski B, Warnke C.
Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.
Neurology. 2019 Apr 5. pii: 10.1212/WNL.0000000000007451. doi: 10.1212/WNL.0000000000007451. [Epub ahead of print]
Summary(link is external)
Sorensen PS, Sellebjerg F.
Pulsed immune reconstitution therapy in multiple sclerosis.
Ther Adv Neurol Disord. 2019 Mar 28;12:1756286419836913. doi: 10.1177/1756286419836913. eCollection 2019. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Kallmann BA, Tiel-Wilck K, Kullmann JS, Engelmann U, Chan A.
Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study.
Ther Adv Neurol Disord. 2019 Mar 27;12:1756286419835077. doi: 10.1177/1756286419835077. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Rotstein D, Montalban X.
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis.
Nat Rev Neurol. 2019 Apr 2. doi: 10.1038/s41582-019-0170-8. [Epub ahead of print] Review.
Summary(link is external)
Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR.
Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
Mult Scler Relat Disord. 2019 Mar 26;31:65-71. doi: 10.1016/j.msard.2019.03.017. [Epub ahead of print]
Summary(link is external)
Azman A, Poyade M, Overell J.
Towards a more user-friendly medication information delivery to people living with multiple sclerosis: a case study with alemtuzumab.
Adv Exp Med Biol. 2019;1120:67-82. doi: 10.1007/978-3-030-06070-1_6.
Summary(link is external)
Drugs in development
Pardini M, Cutter G, Sormani MP.
Multiple sclerosis: clinical trial design 2019.
Curr Opin Neurol. 2019 Apr 3. doi: 10.1097/WCO.0000000000000697. [Epub ahead of print]
Summary(link is external)
Grech LB, Butler E, Stuckey S, Hester R.
Neuroprotective benefits of antidepressants in multiple sclerosis: are we missing the mark?
J Neuropsychiatry Clin Neurosci. 2019 Apr 3:appineuropsych18070164. doi: 10.1176/appi.neuropsych.18070164. [Epub ahead of print]
Summary(link is external)
Other
Thomson A, Horne R, Chung C, Marta M, Giovannoni G, Palace J, Dobson R.
Visibility and representation of women in multiple sclerosis research.
Neurology. 2019 Apr 9;92(15):713-719. doi: 10.1212/WNL.0000000000007276. Epub 2019 Mar 20. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Other treatments
Noorani I, Lodge A, Vajramani G, Sparrow O.
The effectiveness of percutaneous balloon compression, thermocoagulation, and glycerol rhizolysis for trigeminal neuralgia in multiple sclerosis.
Neurosurgery. 2019 Apr 8. pii: nyz103. doi: 10.1093/neuros/nyz103. [Epub ahead of print]
Summary(link is external)
Mehrabani S, Askari G, Miraghajani M, Tavakoly R, Arab A.
Effect of coenzyme Q10 supplementation on fatigue: A systematic review of interventional studies.
Complement Ther Med. 2019 Apr;43:181-187. doi: 10.1016/j.ctim.2019.01.022. Epub 2019 Jan 23. Review.
Summary(link is external)
Porcari B, Russo M, Naro A, La Via C, Pullia M, Accorinti M, De Luca R, Calabrò RS.
Effects of osteopathic manipulative treatment on patients with multiple sclerosis: A pilot study.
Complement Ther Med. 2019 Apr;43:154-156. doi: 10.1016/j.ctim.2019.01.023. Epub 2019 Jan 30.
Summary(link is external)
Friedman D, French JA, Maccarrone M.
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.
Lancet Neurol. 2019 May;18(5):504-512. doi: 10.1016/S1474-4422(19)30032-8. Epub 2019 Mar 22. Review.
Summary(link is external)
Rehabilitation
Juckes FM, Marceniuk G, Seary C, Stevenson VL.
A cohort study of functional electrical stimulation in people with multiple sclerosis demonstrating improvements in quality of life and cost-effectiveness.
Clin Rehabil. 2019 Apr 10:269215519837326. doi: 10.1177/0269215519837326. [Epub ahead of print]
Summary(link is external)
Pawik M, Kowalska J, Rymaszewska J.
The effectiveness of whole-body cryotherapy and physical exercises on the psychological well-being of patients with multiple sclerosis: A comparative analysis.
Adv Clin Exp Med. 2019 Apr 5. doi: 10.17219/acem/104529. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Mokhtarzade M, Agha-Alinejad H, Motl RW, Negaresh R, Baker JS, Zimmer P.
Weight control and physical exercise in people with multiple sclerosis: Current knowledge and future perspectives.
Complement Ther Med. 2019 Apr;43:240-246. doi: 10.1016/j.ctim.2019.02.006. Epub 2019 Feb 8. Review.
Summary(link is external)
Alphonsus KB, Su Y, D'Arcy C.
The effect of exercise, yoga and physiotherapy on the quality of life of people with multiple sclerosis: Systematic review and meta-analysis.
Complement Ther Med. 2019 Apr;43:188-195. doi: 10.1016/j.ctim.2019.02.010. Epub 2019 Feb 10.
Summary(link is external)
Riemann-Lorenz K, Wienert J, Streber R, Motl RW, Coote S, Heesen C.
Long-term physical activity in people with multiple sclerosis: exploring expert views on facilitators and barriers.
Disabil Rehabil. 2019 Mar 23:1-13. doi: 10.1080/09638288.2019.1584253. [Epub ahead of print]
Summary(link is external)
Dennett R, Coulter E, Paul L, Freeman J.
A qualitative exploration of the participants' experience of a web-based physiotherapy program for people with multiple sclerosis: Does it impact on the ability to increase and sustain engagement in physical activity?
Disabil Rehabil. 2019 Mar 23:1-8. doi: 10.1080/09638288.2019.1582717. [Epub ahead of print]
Summary(link is external)
Maggio MG, Russo M, Cuzzola MF, Destro M, La Rosa G, Molonia F, Bramanti P, Lombardo G, De Luca R, Calabrò RS.
Virtual reality in multiple sclerosis rehabilitation: A review on cognitive and motor outcomes.
J Clin Neurosci. 2019 Mar 18. pii: S0967-5868(19)30185-7. doi: 10.1016/j.jocn.2019.03.017. [Epub ahead of print] Review.
Summary(link is external)
Bollaert RE, Sandroff BM, Stine-Morrow EAL, Sutton BP, Motl RW.
The intersection of physical function, cognitive performance, aging, and multiple sclerosis: a cross-sectional comparative study.
Cogn Behav Neurol. 2019 Mar;32(1):1-10. doi: 10.1097/WNN.0000000000000179.
Summary(link is external)
Self-management
Hemmatpoor B, Gholami A, Parnian S, Seyedoshohadaee M.
The effect of life skills training on the self-management of patients with multiple sclerosis.
J Med Life. 2018 Oct-Dec;11(4):387-393. doi: 10.25122/jml-2018-0044.
Summary(link is external)
Read the full text of this paper (link is external)
Stem cells
Cuascut FX, Hutton GJ.
Stem cell-based therapies for multiple sclerosis: current perspectives.
Biomedicines. 2019 Mar 30;7(2). pii: E26. doi: 10.3390/biomedicines7020026. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Symptoms and symptom management
Odabas FÖ, Uca AU.
The prevalence of bruxism and related factors in patients with multiple sclerosis: a comparative study.
Arq Neuropsiquiatr. 2019 Mar;77(3):179-183. doi: 10.1590/0004-282X20190017.
Summary(link is external)
Read the full text of this paper (link is external)
Lebrato Hernández L, Prieto León M, Cerdá Fuentes NA, Uclés Sánchez AJ, Casado Chocán JL, Díaz Sánchez M.
Restless legs syndrome in patients with multiple sclerosis: evaluation of risk factors and clinical impact.
Neurologia. 2019 Apr 5. pii: S0213-4853(19)30030-1. doi: 10.1016/j.nrl.2018.12.010. [Epub ahead of print] English, Spanish.
Summary(link is external)
Brochet B, Ruet A.
Cognitive impairment in multiple sclerosis with regards to disease duration and dlinical phenotypes.
Front Neurol. 2019 Mar 20;10:261. doi: 10.3389/fneur.2019.00261. eCollection 2019. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Ferreira APS, de Souza Pegorare ABG, Junior AM, Salgado PR, Medola FO, Christofoletti G.
A controlled clinical trial on the effects of exercise on lower urinary tract symptoms in women with multiple sclerosis.
Am J Phys Med Rehabil. 2019 Mar 29. doi: 10.1097/PHM.0000000000001189. [Epub ahead of print]
Summary(link is external)
Thompson AGB, Sheldon R, Poole N, Varela R, White S, Jones P, Mulley C, Berg A, Blain CRV, Agrawal N.
A new way of rapidly screening for depression in multiple sclerosis using Emotional Thermometers.
Acta Neuropsychiatr. 2019 Mar 27:1-8. doi: 10.1017/neu.2019.1. [Epub ahead of print]
Summary(link is external)
Pineau F, Socha J, Corvol JC, Louapre C, Assouad R, Maillart E, Lubetzki C, Papeix C.
Impact of an adaptive program for cognitive and emotional deficits (ADACOG program) in multiple sclerosis patients with cognitive impairments.
Rev Neurol (Paris). 2019 Mar 22. pii: S0035-3787(18)30408-9. doi: 10.1016/j.neurol.2018.08.008. [Epub ahead of print]
Summary(link is external)
Donaldson E, Patel VP, Shammi P, Feinstein A.
Why sex matters: a cognitive study of people with multiple sclerosis.
Cogn Behav Neurol. 2019 Mar;32(1):39-45. doi: 10.1097/WNN.0000000000000188.
Summary(link is external)
Gromisch ES, Kerns RD, Beauvais J.
I battle pain every single day": Pain-related illness intrusiveness among persons with multiple sclerosis.
Rehabil Psychol. 2019 Mar 21. doi: 10.1037/rep0000273. [Epub ahead of print]
Summary(link is external)
Work
Doesburg D, Vennegoor A, Uitdehaag BMJ, van Oosten BW.
High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate.
Mult Scler Relat Disord. 2019 Mar 16;31:32-37. doi: 10.1016/j.msard.2019.03.011. [Epub ahead of print]
Summary(link is external)


Is a ketogenic diet good for people with multiple sclerosis?
18/05/2022 - 00:00
Researchers assessed whether a ketogenic diet, low in carbohydrates and high in fats, is suitable for people with multiple sclerosis.


Mayzent (siponimod) use expanded in England for secondary progressive multiple sclerosis
03/05/2022 - 00:00
NHS England has agreed that Mayzent can be prescribed for people with active secondary progressive multiple sclerosis whose disability has increased for at least 6 months, unrelated to relapses, and while taking a disease modifying drug.


Can exercise therapy started soon after diagnosis affect the course of MS?
21/04/2022 - 00:00
Researchers have investigated whether the benefits of early treatment, which are well-established for disease modifying drugs, could also be applied to exercise therapy.

Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.